Member Directory - Pharmaceutical Advisory Board

Chair: Charles Flexner


  • Engage industry in conversations and serve as a key resource to identify barriers in development and to encourage production of LA/ER ARV’s
  • Identify additional experts who can make meaningful contributions to LA/ER topic-specific focus groups, including the generation of educational materials and consensus publications.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Receives consulting fees from Gilead Sciences, Merck, Janssen, ViiV Healthcare. Has an ownership interest in Navigen LLC, and receives grant funding from Gilead Sciences.

After his medicinal chemistry PhD and a Marie Curie Fellowship at Utrecht University, Lluis Ballell Pagès joined GlaxoSmithKline in 2005 to lead different preclinical infectious diseases projects and setup the Open Lab..

Conflict of Interest: Holds intellectual property rights/patent with, and has an ownership interest in, Janssen.

Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs.

Conflict of Interest: None disclosed.

Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina.

Conflict of Interest: None disclosed.

Kati Vandermeulen, M.SC., is a Senior Director, Compound Development Team Leader at Janssen Infectious Diseases Research and Development in Beerse Belgium.

Conflict of Interest: Has no real or apparent conflicts of interest to report.